> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ardelyx Stock Surges 6%, Adding $44 Million, After Quarterly Loss Nearly Disappears
- URL: https://www.bullished.co/ardelyx-stock-surges-6-adding-44-million-after-quarterly-loss-nearly-disappears-caf9ef3f/
- Published: 2026-11-04T15:13:03.000Z
- Updated: 2026-11-04T15:13:03.000Z
- Description: The drugmaker kept its 2026 targets as IBSRELA sales rose 23% and its net loss narrowed to $737,000.
- Author: Matteo Parrino
- Tags: Markets, ARDX, Industry: Healthcare

[Ardelyx](https://www.bullished.co/tag/ardx/) shares climbed 5.61% to $3.20 in Wednesday trading as of 10:11 a.m. ET, adding $44 million in market value, a day after the drugmaker reported a quarterly net loss of [only $737,000](https://finance.yahoo.com/healthcare/articles/ardelyx-q3-earnings-snapshot-211951193.html?ref=bullished.co).

## IBSRELA Carries The Quarter

Ardelyx, which sells the tenapanor-based medicines IBSRELA and XPHOZAH, released results after Tuesday's close: [revenue of $127.7 million](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000059/ardx-20260930.htm?ref=bullished.co), up 15.7% from a year earlier.

IBSRELA, approved for adults with irritable bowel syndrome with constipation, rose 23% to $96.3 million. XPHOZAH, which lowers serum phosphorus in dialysis patients, [rose only 7%](https://www.sec.gov/Archives/edgar/data/0001437402/000143740226000058/ardx-20261103.htm?ref=bullished.co) to $29.2 million.

A late-stage tenapanor trial in chronic idiopathic constipation pushed R&D costs to $25.2 million from $18.1 million.

## Outlook Held, 2027 Profit Targeted

Management kept all of its 2026 targets, including operating expenses under $500 million. It is targeting profitability in 2027.

The move was on pace to be the stock's biggest one-day gain since May 4, when it rose 6.1%.

## A Stock Still Down 48%

Even with Wednesday's gain, Ardelyx shares were down about 48% for the year as of Tuesday's close, while the S&P 500 was up about 11% over the same span. The stock sits far below its highest close of the past year, set on January 21.

Ardelyx's market value stood at $826 million in Wednesday morning trading.

### Sources

- [Ardelyx: Q3 Earnings Snapshot](https://finance.yahoo.com/healthcare/articles/ardelyx-q3-earnings-snapshot-211951193.html?ref=bullished.co) — Associated Press
- [Ardelyx reaffirms 2026 IBSRELA $350M-$370M guidance while targeting profitability in 2027 (NASDAQ:ARDX) | Seeking Alpha](https://seekingalpha.com/news/4664436-ardelyx-reaffirms-2026-ibsrela-350m-370m-guidance-while-targeting-profitability-in-2027?ref=bullished.co) — seekingalpha.com
- [Ardelyx: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/11/ardelyx-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [BTIG Remains a Buy on Ardelyx (ARDX) - The Globe and Mail](https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8604565/btig-remains-a-buy-on-ardelyx-ardx/?ref=bullished.co) — theglobeandmail.com
- [Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates](https://finance.yahoo.com/markets/stocks/articles/ardelyx-ardx-q3-earnings-key-213001884.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [The company's filing (Ardelyx)](https://www.sec.gov/Archives/edgar/data/0001437402/000143740226000058/ardx-20261103.htm?ref=bullished.co) — SEC filing
- [Ardelyx — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1437402/000143740226000059/ardx-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Ardelyx

- [Ardelyx CEO Says 'We All Need To Be Patient' On Xphozah Outlook As Revenue Rises 7% To $29.2 Million](https://www.bullished.co/ardelyx-ceo-says-we-all-need-to-be-patient-on-xphozah-outlook-as-revenue-rises-7-to-29-2-719d7092/)
- [Ardelyx Faces A New Securities Class Action Reaching Back To January 2025](https://www.bullished.co/ardelyx-faces-a-new-securities-class-action-reaching-back-to-january-2025-77e98c53/)
- [Ardelyx's IBSRELA Sales Climb 23% To $96.3 Million, Cutting Its Quarterly Loss To $0.7 Million](https://www.bullished.co/ardelyxs-ibsrela-sales-climb-23-to-96-3-million-cutting-its-quarterly-loss-to-0-7-million-c0fe23e1/)

[All Ardelyx (ARDX) coverage →](https://www.bullished.co/tag/ardx/)